Presenter(s): John Mariani, MD
Target Audience: This activity is designed for physicians, nurses, and physician assistants. This activity is accredited for physicians, nurses, and physician assistants.
Credit Designations Available: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours
Webinar Description: Extended-release injectable buprenorphine products are becoming available commercially and there are several formulations on the market. However there is minimal clinical experience with using these products in patients with opioid use disorder and who are experiencing precipitated withdrawal. It is essential for healthcare professionals to understand and be aware of this treatment modality for OUD to share with patients as part of treatment options. Opioids remain the leading cause of fatal overdose in the US, and highly potent synthetic opioids are the most common opioid responsible for fatal overdoses, the rate of which continues to increase. This training will present data on the current state of opioid use disorder in the US, review injectable extended release buprenorphine products as well as the use of extended-release buprenorphine products for patients using fentanyl, and discuss the possible role for these treatments.
Educational Objectives:
Requirements for Successful Activity Completion: To complete this activity and obtain your Certificate, please follow the steps below: